Selected research
Market Structure
Global Veterinary Immunomodulators Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Veterinary Immunomodulators market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Veterinary Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Veterinary Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Veterinary Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Veterinary Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Veterinary Immunomodulators include Biogenesis Bago, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Elanco Animal Health, ImmunoVet Ltd., MSD Animal Health, Phibro Animal Health Corporation, Vetoquinol S.A. and Zoetis, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Veterinary Immunomodulators market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Veterinary Immunomodulators and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Veterinary Immunomodulators sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Veterinary Immunomodulators market size, projected growth trends, production technologies, key applications, and end-use industries.
Veterinary Immunomodulators Segment by Company
Biogenesis Bago
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Elanco Animal Health
ImmunoVet Ltd.
MSD Animal Health
Phibro Animal Health Corporation
Vetoquinol S.A.
Zoetis, Inc.
Veterinary Immunomodulators Segment by Type
Injectable
Topical
Oral
Others
Veterinary Immunomodulators Segment by Application
Online Sales
Offline Sales
Veterinary Immunomodulators Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Veterinary Immunomodulators market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Veterinary Immunomodulators and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Veterinary Immunomodulators.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Veterinary Immunomodulators market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Veterinary Immunomodulators manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Veterinary Immunomodulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Veterinary Immunomodulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Injectable
- Topical
- Oral
- Others
Applications
- Online Sales
- Offline Sales
Companies covered
- Biogenesis Bago
- Boehringer Ingelheim Animal Health
- Ceva Santé Animale
- Elanco Animal Health
- ImmunoVet Ltd.
- MSD Animal Health
- Phibro Animal Health Corporation
- Vetoquinol S.A.
- Zoetis, Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Veterinary Immunomodulators Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Veterinary Immunomodulators Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Veterinary Immunomodulators Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Veterinary Immunomodulators Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Veterinary Immunomodulators Market Dynamics
- 2.1 Veterinary Immunomodulators Industry Trends
- 2.2 Veterinary Immunomodulators Industry Drivers
- 2.3 Veterinary Immunomodulators Industry Opportunities and Challenges
- 2.4 Veterinary Immunomodulators Industry Restraints
3 Veterinary Immunomodulators Market by Manufacturers
- 3.1 Global Veterinary Immunomodulators Revenue by Manufacturers (2021-2026)
- 3.2 Global Veterinary Immunomodulators Sales by Manufacturers (2021-2026)
- 3.3 Global Veterinary Immunomodulators Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Veterinary Immunomodulators Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Veterinary Immunomodulators Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Veterinary Immunomodulators Manufacturers, Product Type & Application
- 3.7 Global Veterinary Immunomodulators Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Veterinary Immunomodulators Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Veterinary Immunomodulators Players Market Share by Revenue in 2025
- 3.8.3 2025 Veterinary Immunomodulators Tier 1, Tier 2, and Tier 3
4 Veterinary Immunomodulators Market by Type
- 4.1 Veterinary Immunomodulators Type Introduction
- 4.1.1 Injectable
- 4.1.2 Topical
- 4.1.3 Oral
- 4.1.4 Others
- 4.2 Global Veterinary Immunomodulators Sales by Type
- 4.2.1 Global Veterinary Immunomodulators Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Veterinary Immunomodulators Sales by Type (2021-2032)
- 4.2.3 Global Veterinary Immunomodulators Sales Market Share by Type (2021-2032)
- 4.3 Global Veterinary Immunomodulators Revenue by Type
- 4.3.1 Global Veterinary Immunomodulators Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Veterinary Immunomodulators Revenue by Type (2021-2032)
- 4.3.3 Global Veterinary Immunomodulators Revenue Market Share by Type (2021-2032)
5 Veterinary Immunomodulators Market by Application
- 5.1 Veterinary Immunomodulators Application Introduction
- 5.1.1 Online Sales
- 5.1.2 Offline Sales
- 5.2 Global Veterinary Immunomodulators Sales by Application
- 5.2.1 Global Veterinary Immunomodulators Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Veterinary Immunomodulators Sales by Application (2021-2032)
- 5.2.3 Global Veterinary Immunomodulators Sales Market Share by Application (2021-2032)
- 5.3 Global Veterinary Immunomodulators Revenue by Application
- 5.3.1 Global Veterinary Immunomodulators Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Veterinary Immunomodulators Revenue by Application (2021-2032)
- 5.3.3 Global Veterinary Immunomodulators Revenue Market Share by Application (2021-2032)
6 Global Veterinary Immunomodulators Sales by Region
- 6.1 Global Veterinary Immunomodulators Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Veterinary Immunomodulators Sales by Region (2021-2032)
- 6.2.1 Global Veterinary Immunomodulators Sales by Region (2021-2026)
- 6.2.2 Global Veterinary Immunomodulators Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Veterinary Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Veterinary Immunomodulators Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Veterinary Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Veterinary Immunomodulators Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Veterinary Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Veterinary Immunomodulators Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Veterinary Immunomodulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Veterinary Immunomodulators Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Veterinary Immunomodulators Revenue by Region
- 7.1 Global Veterinary Immunomodulators Revenue by Region
- 7.1.1 Global Veterinary Immunomodulators Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Veterinary Immunomodulators Revenue by Region (2021-2026)
- 7.1.3 Global Veterinary Immunomodulators Revenue by Region (2027-2032)
- 7.1.4 Global Veterinary Immunomodulators Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Veterinary Immunomodulators Revenue (2021-2032)
- 7.2.2 North America Veterinary Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Veterinary Immunomodulators Revenue (2021-2032)
- 7.3.2 Europe Veterinary Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Veterinary Immunomodulators Revenue (2021-2032)
- 7.4.2 Asia-Pacific Veterinary Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Veterinary Immunomodulators Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Veterinary Immunomodulators Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Biogenesis Bago
- 8.1.1 Biogenesis Bago Company Information
- 8.1.2 Biogenesis Bago Business Overview
- 8.1.3 Biogenesis Bago Veterinary Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Biogenesis Bago Veterinary Immunomodulators Product Portfolio
- 8.1.5 Biogenesis Bago Recent Developments
- 8.2 Boehringer Ingelheim Animal Health
- 8.2.1 Boehringer Ingelheim Animal Health Company Information
- 8.2.2 Boehringer Ingelheim Animal Health Business Overview
- 8.2.3 Boehringer Ingelheim Animal Health Veterinary Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Boehringer Ingelheim Animal Health Veterinary Immunomodulators Product Portfolio
- 8.2.5 Boehringer Ingelheim Animal Health Recent Developments
- 8.3 Ceva Santé Animale
- 8.3.1 Ceva Santé Animale Company Information
- 8.3.2 Ceva Santé Animale Business Overview
- 8.3.3 Ceva Santé Animale Veterinary Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Ceva Santé Animale Veterinary Immunomodulators Product Portfolio
- 8.3.5 Ceva Santé Animale Recent Developments
- 8.4 Elanco Animal Health
- 8.4.1 Elanco Animal Health Company Information
- 8.4.2 Elanco Animal Health Business Overview
- 8.4.3 Elanco Animal Health Veterinary Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Elanco Animal Health Veterinary Immunomodulators Product Portfolio
- 8.4.5 Elanco Animal Health Recent Developments
- 8.5 ImmunoVet Ltd.
- 8.5.1 ImmunoVet Ltd. Company Information
- 8.5.2 ImmunoVet Ltd. Business Overview
- 8.5.3 ImmunoVet Ltd. Veterinary Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 ImmunoVet Ltd. Veterinary Immunomodulators Product Portfolio
- 8.5.5 ImmunoVet Ltd. Recent Developments
- 8.6 MSD Animal Health
- 8.6.1 MSD Animal Health Company Information
- 8.6.2 MSD Animal Health Business Overview
- 8.6.3 MSD Animal Health Veterinary Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 MSD Animal Health Veterinary Immunomodulators Product Portfolio
- 8.6.5 MSD Animal Health Recent Developments
- 8.7 Phibro Animal Health Corporation
- 8.7.1 Phibro Animal Health Corporation Company Information
- 8.7.2 Phibro Animal Health Corporation Business Overview
- 8.7.3 Phibro Animal Health Corporation Veterinary Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Phibro Animal Health Corporation Veterinary Immunomodulators Product Portfolio
- 8.7.5 Phibro Animal Health Corporation Recent Developments
- 8.8 Vetoquinol S.A.
- 8.8.1 Vetoquinol S.A. Company Information
- 8.8.2 Vetoquinol S.A. Business Overview
- 8.8.3 Vetoquinol S.A. Veterinary Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Vetoquinol S.A. Veterinary Immunomodulators Product Portfolio
- 8.8.5 Vetoquinol S.A. Recent Developments
- 8.9 Zoetis, Inc.
- 8.9.1 Zoetis, Inc. Company Information
- 8.9.2 Zoetis, Inc. Business Overview
- 8.9.3 Zoetis, Inc. Veterinary Immunomodulators Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Zoetis, Inc. Veterinary Immunomodulators Product Portfolio
- 8.9.5 Zoetis, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Veterinary Immunomodulators Value Chain Analysis
- 9.1.1 Veterinary Immunomodulators Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Veterinary Immunomodulators Production Mode & Process
- 9.2 Veterinary Immunomodulators Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Veterinary Immunomodulators Distributors
- 9.2.3 Veterinary Immunomodulators Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst